BGPT: Paper Review: Targeting the SHOC2–RAS interaction in RAS-mutant cancers

Fuel Your Discoveries

Quick Explanation Copied

SHOC2 emerges as an actionable, nucleotide-state-dependent RAS co-dependency

This Nature paper reports that SHOC2 is required specifically in RAS Q61* contexts, provides orthogonal biochemical/structural evidence for a binary SHOC2–NRAS(Q61R) complex, and describes tool inhibitors (peptide + small molecule) that disrupt the interface and suppress MAPK signaling and tumor growth in preclinical models.

Long Explanation

Paper Review (science-first, skeptical, evidence-linked)

Paper: 10.1038/s41586-025-08931-1

Central claim: SHOC2 is a RAS Q61*-enriched dependency; oncogenic NRAS(Q61R) forms a direct binary interaction with SHOC2 (structure supported), and small-molecule/peptide binders that disrupt this interface suppress MAPK signaling and tumor growth in RAS-mutant models.

Visual overview: “dependency → interface → disruptor → pathway shutdown”

Evidence anchor: The chain is explicitly presented across the paper’s genetic dependency mapping, biophysical/structural validation, and pharmacological displacement + downstream pathway effects.

Key biochemical potency: interface disruptors (TR-FRET / SPR)

The paper reports SHOC2 binding/disruption potencies across a small-molecule series and a peptide, including TR-FRET competitive-binding IC50 values and/or SPR Kd values (Table 1).

Skeptical note: Potency comparisons are sensitive to assay formats, protein constructs (e.g., SHOC2 80–582 vs full-length), nucleotide-loading conditions, and cellular exposure/efflux. The paper explicitly notes activity shifts when moving from in vitro to cell assays and includes permeability measurements.

Potency specificity check: “inactive enantiomer” and “interface-resistant SHOC2”

The paper argues specificity via (i) a genetically resistant SHOC2 mutant (G290A) that abolishes compound 6 activity in the SHOC2–NRAS(Q61*) TR-FRET binding/displacement assay, (ii) an inactive enantiomer compound 7 that is inert in NanoBiT and does not shift the SHOC2–RAS PPI in tested models.

Important: This panel is a logic visualization based on whether the paper reports activity/no activity under each control condition; it is not a numeric re-plot of TR-FRET IC50 values.

Dependency enrichment: RAS Q61* sensitivity to SHOC2

The paper uses (i) a Ba/F3 isogenic CRISPR screen across RAS hotspot mutations and isoforms and (ii) DepMap analysis to show that SHOC2 is the most prominent hit in RAS Q61* models, with weaker/absent dependency in G12 contexts.

Limit: No exact DepMap effect-size numbers for SHOC2 selectivity are in the excerpt you provided; the plot is therefore a qualitative “directionality” visualization only.

Mechanistic core: binary SHOC2–NRAS(Q61R) interface, mapped structurally

The paper reports that SHOC2 forms a stable binary complex with nucleotide-state-dependent oncogenic RAS. Specifically, AUC sedimentation velocity and SPR binding show that wild-type NRAS/KRAS loaded with GDP do not form a larger complex, whereas GTP-loaded Q61R mutants do, producing a binary species; SPR Kd values are reported as ~11 µM for NRAS(Q61R) and ~12 µM for KRAS(Q61R) (in their stated conditions).

The paper further provides an X-ray co-crystal structure of NRAS(Q61R) bound to SHOC2 at 2.53 Å resolution, describing interface chemistry including salt bridges, hydrogen bonds, and hydrophobic contacts; it also discusses how NRAS switch regions engage LRR residues on SHOC2 and notes that the mutation R61 forms a direct hydrogen bond to SHOC2 T264 (contrasted with MRAS interactions described in prior work).

Downstream pathway output: MAPK shutdown without changing RAS-GTP load (as reported)

The lead small molecule (compound 6) is reported to reduce MAPK signaling readouts (decreased pERK/pMEK) specifically in RAS-mutant settings (with an example contrast against BRAF(V600E) contexts), while leaving RAS-GTP loading unaffected in their assays. The paper also reports increases in inhibited CRAF (phospho-S259), consistent with reduced SMP activity following SHOC2–RAS PPI disruption.

Therapeutic “logic” and translational bottlenecks (skeptical appraisal)

What looks strong

Multi-layer evidence for target: genetics (dependency), biophysics (AUC/SPR), structure (X-ray interface), and pharmacology (PPI displacement + pathway readouts).
Specificity controls are mechanistically relevant: SHOC2(G290A) resistance logic and an inactive enantiomer for non-mechanistic effects.

What remains uncertain / potential blind spots

Cell-line to tumor translation: The strongest evidence relies on cell lines and xenografts; while xenografts show impaired growth with SHOC2 reduction, the excerpt doesn’t include the full pharmacokinetic/pharmacodynamic detail needed to assess whether durable exposure will be achieved broadly.
Interface redundancy & compensatory circuitry: MAPK signaling is networked; blocking SHOC2–RAS could provoke bypass adaptations. The paper argues selectivity by active-state dependence and shows pathway markers decrease, but adaptation dynamics across longer timelines are not fully contained in the provided excerpt.
Assay context: PPI assays use recombinant proteins, constructs (e.g., SHOC2(80–582)), and in vitro nucleotide-loading; while structure aligns with these assays, binding landscapes in living cells (local concentration, membrane lipid environment, crowding) may shift effective kinetics and selectivity.

Concrete falsification routes (what would change the conclusion)

Show that compound 6 displacement (TR-FRET/NanoBiT) occurs but MAPK/pERK does not decrease in multiple independent NRAS(Q61*) models—would weaken causal link between interface disruption and pathway shutdown.
Demonstrate that SHOC2 knockdown affects viability through off-target functions unrelated to the RAS interface (e.g., independent phenotypes in contexts where interface binding is disrupted but SHOC2 remains present).

Data & reproducibility anchors (from the paper)

Structures deposited in PDB: 9BTM, 9BTN, 9OVJ.
RNA-seq deposited in SRA: BioProject PRJNA1010709.
Small-molecule crystallography: CCDC 2353396.

Next-step explorations (BGPT shortcuts)

Author reviews (bespoke BGPT links)

Feedback:

Updated: March 25, 2026